Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:

Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05877404
• Other study ID #: IRB00097221
• Secondary ID: WFBCCC 99323P30C
• Status: Terminated
• Start date: August 15, 2023
• Est. completion date: February 28, 2024

Study information

• Verified date: April 2024
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.

Description:

Primary Objective: Proportion of physicians reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients.

Secondary Objectives:

• Explore the use of informed consent in tumor genetic testing in endometrial cancer

• Explore clinician confidence in utilizing tumor genetic testing to guide treatment decisions.

• Explore the impact of recent publications regarding immunotherapy on the use of tumor genetic testing in endometrial cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 112
• Est. completion date: February 28, 2024
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Member of the Society of Gynecologic Oncology

• Gynecologic Oncologist or Gynecologic Oncology Fellow-in-Training

Related Conditions & MeSH terms

• Endometrial Cancer
• Endometrial Neoplasms

Intervention

Other:
• Surveys
Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.

Locations

Country	Name	City	State
United States	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of providers reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients	The primary outcome is to estimate the percentage of providers who report the use of different tumor testing strategies. Investigators will calculate the frequencies of responses to each testing strategy and then compare the percentage of physicians who choose different strategies, using a chi-square or Fisher's exact test.	4 months
Secondary	Frequency of providers using different strategies of informed consent in tumor genetic testing in endometrial cancer	Investigators will calculate the number of frequencies of different tumor testing informed consent strategies among physicians.	4 months
Secondary	Number of providers reporting confidence in utilizing tumor genetic testing to guide treatment decisions	Investigators will calculate the number of providers who are very confident, moderately confident, a little confident or not at all confident in their ability to explain tumor testing strategies and results.	4 months
Secondary	Number of providers who change their counseling or testing strategies for endometrial cancer	Investigators will compare the number of providers who have changed their counseling or testing strategy based on their familiarity with recent publications regarding immune-checkpoint inhibitors in advanced and recurrent endometrial cancer using a chi-square or Fisher's exact test.	4 months